Search live federal opportunities

Not fixed price and not competetive. Negotiated award based on Broad Agency Announcement

National Contract Award to AvKARE, LLC. (SPE2D2-26-D-0002) for Telmisartan Tablets originally solicited under SPE2D2-24-R-0015.

The Naval Air Systems Command (NAVAIR) awarded a Firm Fixed Price (FFP) and Cost Plus Fixed Fee (CPFF) Delivery Order under Basic Ordering Agreement (BOA) N00019-23-G-0002 to Lockheed Martin Rotary and Mission Systems (LM RMS), Owego, New York, for the System

NATIONAL CONTRACT SPE2D2-23-D-0001 ESTRADIOL TABLETS

VISN 2 Upstate Home Oxygen Contract

Lease number GS-02P-LNY00464 awarded pursuant to RLP 8NY2634 in the Jamaica, NY area for 18,810 ABOA SF of office space. The lease is for a 15 year firm term.

SPE2D2-25-D-0007 Hydrocodone-Acetaminophen Award

SPE2D2-24-D-0007 Finasteride Tablets Award

NATIONAL CONTRACT SPE2D223D0005 LISINOPRIL HCTZ TABLETS

Sertraline HCL Tablets 25MG in 30, 90, 180 and 500 Count bottles, Sertraline HCL Tablets in 50MG in 30, 90, 180, and 500 Count bottles and Sertraline HCL Tablets in 30, 60, 90, 180 and 500 Count bottlles.

NATIONAL CONTRACT SPE2D2-23-D-0002 BUPROPION HCL ER

SPE2D2-26-D-0012 Sertraline Tablets Follow-On Award

Modification to exercise Option Year 1 for Lamotrigine ER Tablets is attached.

AWARD OF CELECOXIB CAPSULES DLA TROOP SUPPORT NATIONAL CONTRACT

SPE2D2-26-D-0010 Celecoxib Capsules

NATIONAL CONTRACT SPE2D2-22-D-0144 VALSARTAN

SPE2D2-25-D-0012 Pramipexole Tablets Award

Award a contract for Sewage and wastewater Utility service for USMMA on 3/31/2026 on a Sole Source basis. See the attached justification.

Fexofenadine Tablets SPE2D2-25-D-0005 Option 1

Award for Fluconazole Tablets solicited under SPE2D2-25-R-0009.

SPE2D2-22-D-0150 P00007 to invoke Option Year 3 SPE2D2-22-D-0150 P00006 Mass Modification based on Executive Orders. SPE2D2-22-D-0150 P00005 to invoke Option Year 2 SPE2D2-22-D-0150 P00003 to invoke Option Year 1 SPE2D2-22-D-0150 P00002 To incorporate Drug

1. Option #1 is hereby executed for the period July 2, 2026 through July 1, 2027. 2. All other terms and conditions remain unchanged.

HEMATOLOGY Cost-Per-Reportable-Result for VISN 2.